Open-label clinical phase 1/2 study to assess the safety and efficacy of the SpectraCure P18 System and verteporfin for injection for the treatment of primary localized prostate cancer

Prior treatment

• Use of Alpha-reductase inhibitors (ARIs) within 90 days of enrolment.
• On-going therapy with a photosensitizing agent.
• Enrolment in another therapeutic clinical study within 3 month prior to enrolment and throughout the study.
• Prior radical surgery for carcinoma of the prostate, prior pelvic radiation, prior TURP, prior cryosurgery of the prostate.
• Prior treatment with any form of brachytherapy.
• Previous androgen deprivation therapy (ADT) or chemotherapy for prostate cancer.
• Prior or current bleeding diathesis.

Other illness

• Evidence of locally advanced, regional pelvic lymph node metastasis, or metastatic disease.
• Mental incapacity or psychiatric illness that would interfere with the subject’s ability to understand and give informed consent or to complete follow-up visits according to the judgement of the investigator.
• Contraindication for photosensitizer including: a. Porphyria or other diseases exacerbated by light. b. Known hypersensitivity to verteporfin for injection (VFI) or to any of the excipients. c. Known allergies to porphyrins.
• Has known hypersensitivity to pancuronium bromide, atricurium or cisatricurium
• High volume GG1 disease in the contralateral prostate, outside of the ablation zone. High volume is defined as >1 core of GG1 with a linear amount of carcinoma >6mm.

Lab values

• Any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision).
• Contraindication for MRI/Gadolinium contrast such as: implants, hip prosthesis, severe renal impairment (glomerular filtration rate [GFR] <30 mL/min/1.73m2), or previous contrast reactions.

Other

• Any suspicious for, probable, or definite extracapsular extension on pretreatment MRI
• Contralateral PIRADS 4/5 lesion (even if negative targeted biopsy)
• Tumors known to be eroding into a major blood vessel in or adjacent to the illumination site.

• Subjects ≥ 18 years.
• Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3.
• Adequate renal function as defined by creatinine ≤ 1.5 mg /dl
• Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum glutamate-oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and alanine transaminase (ALT) ≤ 3 times the upper limit of normal.
• Only persons who use an effective method of contraception (condom is recommended) or whose sexual partner is de facto unable to conceive a child for other reasons are included.
• Signed Informed Consent.
• Histologically confirmed organ-confined prostate cancer diagnosed within the last 9 months. Including subjects on active surveillance with evidence of disease progression and a prostate biopsy not older than 9 months. a. This prostate biopsy should be targeted and systematic (transperineal or transrectal are both acceptable) and include both systematic sampling with a minimum of 8 cores (4 right, 4 left) as well as MRI fusion targeted cores. The minimum number of targeted cores is two (2) but more may be included at the discretion of the surgeon.
• Gleason Score 7 (3+4 or 4+3).
• PSA ≤ 15 ng/mL.
• Lesion volume on mpMRI < 1.5 cm3.
• Adequate stage imaging such as pelvic CT/MRI/PET scan within the last 6 months confirming localized cancer. • Bone scan is optional if PSA < 10 ng/mL.
• Treatment target volume <50 cm3 defined by TRUS or MRI.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Expected survival ≥ 36 months.